Rare Cancers, Common Need

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cancer immunotherapy, and in particular immune checkpoint blockade, has transformed oncology with the potential for durable responses even in patients with metastatic disease. To date, regulatory approvals and clinical trials have focused on the study of these agents in relatively more common tumor types, such as melanoma, non-small cell lung cancer, bladder cancer, and kidney cancer, amongst others.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
S1609 DART clinical study chair; Assistant professor of medicine, UC San Diego Cancer Center;
Assistant director, Clinical Trials Office, Moores Cancer Center; Investigator, SWOG early therapeutics and rare cancers committee
S1609 DART translational medicine study chair; assistant professor, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine; Co-director, Developmental Therapeutics, Lurie Cancer Center; Vice chair, SWOG early therapeutics and rare cancers committee
Razelle Kurzrock
S1609 DART senior study chair; Senior deputy center director, Moores Cancer Center; Chief, Division of Hematology and Oncology, UC San Diego; Chair, SWOG early therapeutics and rare cancers committee

YOU MAY BE INTERESTED IN

President Joe Biden’s proposed Advanced Research Projects Agency-Health would be a welcome partner to NCI—particularly in conducting large, collaborative clinical investigations, NCI Director Ned Sharpless said.“I think having ARPA-H as part of the NIH is good for the NCI,” Sharpless said April 11 in his remarks at the annual meeting of the American Association for Cancer Research. “How this would fit with the ongoing efforts in cancer at the NCI is still something to work out.”
S1609 DART clinical study chair; Assistant professor of medicine, UC San Diego Cancer Center;
Assistant director, Clinical Trials Office, Moores Cancer Center; Investigator, SWOG early therapeutics and rare cancers committee
S1609 DART translational medicine study chair; assistant professor, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine; Co-director, Developmental Therapeutics, Lurie Cancer Center; Vice chair, SWOG early therapeutics and rare cancers committee
Razelle Kurzrock
S1609 DART senior study chair; Senior deputy center director, Moores Cancer Center; Chief, Division of Hematology and Oncology, UC San Diego; Chair, SWOG early therapeutics and rare cancers committee

Login